BRNS
Barinthus Biotherapeutics
$0.60
−$0.00 (−0.17%)Jul 27, 2026
Key metrics
The numbers that frame BRNS today
- Market cap
- $24.55M
- P/E (TTM)
- -0.5
- EV / FCF
- 0.9
- ROIC
- -329.5%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $0.51
- 52wk High
- $1.83
Growth
Revenue and earnings trend for BRNS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about BRNS
Is Barinthus Biotherapeutics a good buy?
No. Barinthus Biotherapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup.
What is the market capitalization of BRNS?
Barinthus Biotherapeutics's market capitalization is $24.55M.
What is the P/E ratio for BRNS stock?
Barinthus Biotherapeutics's current P/E ratio is -0.5.
What is the 52-week high for BRNS stock?
The 52-week high for Barinthus Biotherapeutics is $1.83. The current close of $0.60 is 67.2% below that high.
What is the 52-week low for BRNS stock?
The 52-week low for Barinthus Biotherapeutics is $0.51. The current close of $0.60 is 17.4% above that low.
Does BRNS stock pay dividends?
Barinthus Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BRNS?
Barinthus Biotherapeutics's Debt / Equity ratio is 0.17.